Drugs / Allogenic adipose derived mesenchymal stem cells
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT05933434 Comparator | Mar 2024 → Oct 2030 expected | osteoarthritis, knee | Aarhus University Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogenic adipose derived mesenchymal stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05933434 ↗ |
| Known as | AD-MSC | “Allogenic adipose derived mesenchymal stem cells (AD-MSC)” NCT05933434 ↗ |
| Modality | Cell therapy | “mesenchymal stem cells (AD-MSC)” NCT05933434 ↗ |